A Phase 1b Study Evaluating the Safety, Tolerability,
Pharmacokinetics, and Efficacy of Tarlatamab in Combination
with ZL-1310 with or without Anti-PD-L1 in Participants with
Small Cell Lung Cancer

Lungentumoren

Kleinzelliges Bronchialkarzinom (SCLC)

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Weitere

PD-1 (Programmed cell death protein 1)

PD-L1

Phase IB

AMG 757 20250114 (DeLLphi 313)

Erstlinie

Zweitlinie

<div>A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma</div><div><br /></div>

Plasmozytom (Multiples Myelom)

Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)

TRIMM-3, 64407564MMY1005

Comprehensive Cancer Center Mainfranken

Studien des CCC Mainfranken